Why Is FRTT Stock Up 68% June 24 2026 | CUPR FDA ABSI QNRX FCEL MU Earnings Watch List

Disclosure: I am not a registered financial advisor. This is educational content on market news, economic calendar, and historical trade reviews. Trading involves risk of loss. Past performance does not guarantee future results. Nothing herein is a recommendation to buy or sell any security. Assume I have positions in tickers discussed. Do not make financial decisions based solely on this content. Trade your own decisions.

Wednesday open. The tape has five names running pre-market with very different setups. A 2.51M float pest control company is up 68% with no press release. An FDA-cleared biotech is continuing from last week. A 160,000-share float pharma is up 26%. And Micron reports after the close tonight. Here is what is on the board.

The top gapper this morning is FRTT, Fort Technology. The company listed on Nasdaq on June 8 under ticker FRTT after trading on the TSX Venture Exchange as FORT. Fort makes pest control and remedial repair products. No new press release is on the wire this morning. The 2.51M float is doing 11.48M in volume pre-market, which is 4.5 times the entire float before the opening bell. This is a pure low-float momentum run with no new fundamental catalyst confirmed.

CUPR is up 37% on its FDA 510(k) clearance for MEDIFLY Maggots, which was granted on June 15. Cuprina Holdings received the first U.S. clearance for a Lucilia cuprina maggot debridement product. The stock also resolved its Nasdaq compliance issue in mid-June. The move today is continuation of the FDA catalyst from last week. The company previously completed a reverse stock split in May.

ABSI is up 28%. Absci Corp is an AI-driven drug development company. Leerink Partners initiated with Outperform on June 4 and Guggenheim raised its price target to $15 from $10 on June 15. The lead asset, ABS-201, targets the prolactin receptor with a Phase 2 trial for endometriosis set for Q4 2026. Interim data for androgenetic alopecia is expected later this year. The move today is built on stacked analyst sentiment with a binary clinical data event coming later in 2026.

QNRX is up 26% pre-market. Quoin Pharmaceuticals has a 0.16M share float. That is 160,000 total shares outstanding available to trade. The company announced on June 18 the establishment of a wholly-owned subsidiary in Japan to commercialize QRX003 for Netherton Syndrome, following Orphan Drug Designation from Japan's MHLW. This is a micro-float name where a few hundred thousand dollars in volume moves the stock dramatically in either direction.

MU is up 4.64% continuing the pre-earnings drift from the week preview posted Sunday. Micron reports after the close tonight. The consensus is $19.95 EPS on $34.66B in revenue. HBM demand is the number to watch. On the downside, CBRS dropped 10.58% this morning. Cerebras Systems reported Q1 earnings after the close yesterday. Revenue grew 94% year-over-year to $193.4M. The beat was not enough. Forward guidance disappointed and the stock is giving back a significant portion of its recent gains post-IPO.

The June 22 watch list recap and prior week setups that are continuing this morning:

Thursday remains the most important trading day of the week. The PCE and GDP final print on the same morning sets up the rate narrative into July. Position size and direction going into Thursday close tonight matters.

Fort Technology listed on Nasdaq on June 8, 2026, under ticker FRTT. The company manufactures pest control and remedial repair products and is a majority-owned subsidiary of Nexera Technologies. Market cap at listing was approximately US$46.4 million. There is no new press release this morning. Volume pre-market is 11.48M shares on a 2.51M float. The move is pure float-driven momentum with no confirmed new catalyst on the wire. The stock traded near $1.92 on June 19 and is at $3.02 pre-market today. That is a $1.10/share move in five trading days.

Cuprina Holdings received FDA 510(k) clearance for MEDIFLY Maggots on June 15. This is the first U.S. clearance for a Lucilia cuprina maggot debridement product. Maggot debridement therapy is used for chronic wound treatment. Cuprina also resolved its Nasdaq compliance issues in mid-June after completing a reverse stock split in May. The stock was at $3.97 on June 11 after the compliance announcement and has been moving higher on the FDA clearance. Today's move is continuation of stacked catalysts: Nasdaq compliance resolved plus first-in-class FDA clearance.

Absci is an AI-driven drug development company with a platform that combines generative AI and wet lab biology to design and validate drug candidates. Leerink Partners initiated coverage with Outperform on June 4, citing the company's promising catalyst pipeline. Guggenheim raised its price target to $15 from $10 on June 15. The lead asset ABS-201 targets the prolactin receptor, with a Phase 2 trial for endometriosis planned for Q4 2026 and interim data for androgenetic alopecia expected this year. The float is 108.60M. The move today is momentum off stacked analyst upgrades ahead of clinical data later in 2026.

Quoin Pharmaceuticals has a 0.16M share float. 160,000 shares total. The company announced on June 18 the establishment of a wholly-owned Japanese subsidiary to commercialize QRX003, its lead candidate for Netherton Syndrome, following Orphan Drug Designation from Japan's Ministry of Health, Labour and Welfare. QRX003 is in Phase 2 clinical trials and has orphan drug designation in the U.S., EU, and Japan. A pivotal Phase 3 study is expected to start in H2 2026. On a 160,000-share float, 3.57M in pre-market volume equals more than 22 times the entire float trading hands before the open.